Trevi Therapeutics (TRVI) Total Current Liabilities (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Total Current Liabilities of $7.1 million for Q1 2026, up 3.63% year-over-year from $6.9 million in Q1 2025, and down 27.02% quarter-over-quarter from $9.7 million in Q4 2025.
Trevi Therapeutics (TRVI) Total Current Liabilities (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $7.1 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 3.63% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (up 3.63% YoY), while the FY2025 annual figure was $9.7 million, down 7.23% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $7.1 million, down from $9.7 million in the prior quarter.
- The five-year high for Total Current Liabilities was $15.4 million in Q2 2022, with the low at $4.7 million in Q2 2023.
- The 5-year median for Total Current Liabilities is $9.1 million (2024), against an average of $9.3 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 141.05% in 2022, then sank 69.47% in 2023.
- Trevi Therapeutics' Total Current Liabilities stood at $13.4 million in 2022, then slumped by 56.54% to $5.8 million in 2023, then soared by 80.44% to $10.5 million in 2024, then fell by 7.23% to $9.7 million in 2025, then decreased by 27.02% to $7.1 million in 2026.
- Business Quant data shows TRVI's Total Current Liabilities at $7.1 million in Q1 2026, $9.7 million in Q4 2025, and $9.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 8.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.74 Mn |
| Mar 31, 2026 | 7.12 Mn |
| Dec 31, 2025 | 9.75 Mn |
| Sep 30, 2025 | 9.04 Mn |
| Jun 30, 2025 | 9.24 Mn |
| Mar 31, 2025 | 6.87 Mn |
| Dec 31, 2024 | 10.51 Mn |
| Sep 30, 2024 | 9.12 Mn |
| Jun 30, 2024 | 6.75 Mn |
| Mar 31, 2024 | 5.28 Mn |
| Dec 31, 2023 | 5.82 Mn |
| Sep 30, 2023 | 5.17 Mn |
| Jun 30, 2023 | 4.71 Mn |
| Mar 31, 2023 | 13.20 Mn |
| Dec 31, 2022 | 13.40 Mn |
| Sep 30, 2022 | 14.64 Mn |
| Jun 30, 2022 | 15.43 Mn |
| Mar 31, 2022 | 12.87 Mn |
| Dec 31, 2021 | 12.72 Mn |
| Sep 30, 2021 | 9.91 Mn |